Application of 68GA-labeled CD73 Targeting Probe PET/CT Imaging in the Diagnosis of Malignant Tumor

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-03-01

Study Completion Date

2026-03-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

68Ga-DOTA-dPNE PET/CT imaging was performed on patients with malignant tumors to observe the binding of lesions with the tracer and evaluate the expression of CD73. At the same time, correlation analysis was performed combined with relevant clinical indicators to evaluate the efficacy of 68Ga-DOTA-dPNE in the diagnosis and guidance of malignant tumor patients, and predict the response of targeted therapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Application of the CD73-Targeted Probe ⁶⁸Ga-DOTA-mPNE PET/CT Imaging in the Diagnosis of Malignant Tumors

NCT07023640

Malignant Neoplasms of Brain

RECRUITING NA

Application of 68GA-labeled CD73 Targeting Probe PET/CT Imaging in the Diagnosis of Breast Cancer

NCT06411678

Breast Cancer

RECRUITING EARLY_PHASE1

Dosimetry and Preliminary Clinical Application Study of a Novel Probe Targeting CD73

NCT06995976

Malignant Tumour

RECRUITING EARLY_PHASE1

68Ga-DOTA-F2 PET/CT in Patients With Various Types of Cancer

NCT05637034

Tumor, Solid

UNKNOWN NA

Radiolabelled Nectin-4 Targeted LMW Probe PET/CT in Patients With Lung Lesions

NCT06648317

Lung Cancer, Non-Small Cell Lung Infection

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tumor Immunity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Malignant tumor

Group Type EXPERIMENTAL

68GA-DOTA-dPNE

Intervention Type DRUG

Intravenous administration of 68GA-DOTA-dPNE tracer

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

68GA-DOTA-dPNE

Intravenous administration of 68GA-DOTA-dPNE tracer

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 1: Age: ≥18 years, expected survival ≥12 weeks 2: Without radiotherapy and chemotherapy, surgery or biopsy is feasible to obtain pathological diagnosis 3: Standard Solid Tumor Response Evaluation Criteria (RECIST) version 1.1 with at least one measurable target lesion 4: Obtain written informed consent and be able to follow up

Exclusion Criteria

\- 1: Severe liver and kidney dysfunction. 2: Women who are planning to conceive, pregnant, or breastfeeding, as well as those planning to have children during the study period, are not eligible to participate in this research. Women of childbearing potential must use effective contraception throughout the course of the study.

3: Individuals unable to lie flat for thirty minutes. 4: Suffers from claustrophobia or other mental illnesses 5: Researchers believe that the subject has other conditions that make them unsuitable for inclusion in this study 6: Refuses to join this clinical study

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes